Cardiac contractility is regulated by several neural, hormonal, paracrine, and autocrine factors. Amongst these, signaling through β-adrenergic and serotonin receptors generates the second messenger cyclic AMP (cAMP), whereas activation of natriuretic peptide receptors and soluble guanylyl cyclases generates cyclic GMP (cGMP). Both cyclic nucleotides regulate cardiac contractility through several mechanisms. Phosphodiesterases (PDEs) are enzymes that degrade cAMP and cGMP and therefore determine the dynamics of their downstream effects. In addition, the intracellular localization of the different PDEs may contribute to regulation of compartmented signaling of cAMP and cGMP. In this review, we will focus on the role of PDEs in regulating con...
Pathological cardiac hypertrophy and dysfunction is a response to various stress stimuli and can res...
Cyclic guanosine 3'5'monophosphate (cGMP) is the common downstream second messenger of natriuretic p...
ObjectivesThis study investigated whether myocardial phosphodiesterase-2 (PDE2) is altered in heart ...
Cyclic nucleotide phosphodiesterases regulate cAMP-mediated signaling by controlling intracellular c...
International audienceCyclic nucleotide phosphodiesterases (PDEs) modulate the neuro-hormonal regula...
International audienceCyclic nucleotide phosphodiesterases (PDEs) modulate the neuro-hormonal regula...
CGMP is a central intracellular second-messenger regu-lating numerous cellular functions. In the car...
Background: Cyclic nucleotide phosphodiesterases (PDEs) compromise a family of cyclic-nucleotide hyd...
Cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP) are now recognized a...
Left ventricular hypertrophy leads to heart failure and represents a high risk leading to premature ...
cAMP and cGMP signalling pathways are common targets in the pharmacological treatment of heart failu...
cAMP and cGMP signalling pathways are common targets in the pharmacological treatment of heart failu...
International audienceCyclic AMP regulates a multitude of cellular responses and orchestrates a netw...
International audienceCyclic AMP regulates a multitude of cellular responses and orchestrates a netw...
International audienceCyclic nucleotide phosphodiesterases (PDEs) degrade the second messengers cycl...
Pathological cardiac hypertrophy and dysfunction is a response to various stress stimuli and can res...
Cyclic guanosine 3'5'monophosphate (cGMP) is the common downstream second messenger of natriuretic p...
ObjectivesThis study investigated whether myocardial phosphodiesterase-2 (PDE2) is altered in heart ...
Cyclic nucleotide phosphodiesterases regulate cAMP-mediated signaling by controlling intracellular c...
International audienceCyclic nucleotide phosphodiesterases (PDEs) modulate the neuro-hormonal regula...
International audienceCyclic nucleotide phosphodiesterases (PDEs) modulate the neuro-hormonal regula...
CGMP is a central intracellular second-messenger regu-lating numerous cellular functions. In the car...
Background: Cyclic nucleotide phosphodiesterases (PDEs) compromise a family of cyclic-nucleotide hyd...
Cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP) are now recognized a...
Left ventricular hypertrophy leads to heart failure and represents a high risk leading to premature ...
cAMP and cGMP signalling pathways are common targets in the pharmacological treatment of heart failu...
cAMP and cGMP signalling pathways are common targets in the pharmacological treatment of heart failu...
International audienceCyclic AMP regulates a multitude of cellular responses and orchestrates a netw...
International audienceCyclic AMP regulates a multitude of cellular responses and orchestrates a netw...
International audienceCyclic nucleotide phosphodiesterases (PDEs) degrade the second messengers cycl...
Pathological cardiac hypertrophy and dysfunction is a response to various stress stimuli and can res...
Cyclic guanosine 3'5'monophosphate (cGMP) is the common downstream second messenger of natriuretic p...
ObjectivesThis study investigated whether myocardial phosphodiesterase-2 (PDE2) is altered in heart ...